DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDATED BALANCE SHEETS", the right column header was incorrectly labeled as "March 31, 2022", when it should be labeled "December 31, 2022". The corrected release follows:
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2023.
“Demand for Tyvaso DPI® has been very strong, which resulted in $23 million in revenues in the first quarter of 2023,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “I'm excited about our inhaled platform and orphan lung pipeline as we get ready to launch our Phase 2/3 inhaled clofazimine trial for patients in the second half of 2023.”
Revenue Highlights
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | $ Change | % Change | ||||||||
| (Dollars in thousands) | |||||||||||
| Net revenue – Afrezza | $ | 12,423 | $ | 9,826 | $ | 2,597 | 26 | % | |||
| Net revenue – V-Go | 5,139 | — | $ | 5,139 | * | ||||||
| Revenue – collaborations and services | 11,386 | 2,166 | $ | 9,220 | 426 | % | |||||
| Royalties – collaborations | 11,678 | — | $ | 11,678 | * | ||||||
| Total revenues | $ | 40,626 | $ | 11,992 | $ | 28,634 | 239 | % | |||
___________________
* Not meaningful
Afrezza® net revenue for the first quarter of 2023 increased compared to the same period in 2022 as a result of higher product demand, higher price (including a more favorable gross-to-net adjustment) and a more favorable cartridge mix. V-Go® was acquired in the second quarter of 2022. The increase in collaborations and services revenue reflected that the commercial manufacturing of Tyvaso DPI had not yet commenced in the prior period. Royalties related to Tyvaso DPI, launched in the second quarter of 2022 by United Therapeutics (“UT”), continued to grow based on strong patient demand.
Commercial product gross margin in the first quarter of 2023 was 69% compared to 77% for the same period in 2022 primarily related to the addition of V-Go in the second quarter of 2022 which had a lower gross margin than Afrezza.
Cost of revenue – collaborations and services for the first quarter of 2023 was $10.7 million compared to $8.7 million for the same period in 2022, an increase of $2.0 million, due to an increase in manufacturing activities for Tyvaso DPI.
Research and development expenses for the first quarter of 2023 were $5.6 million compared to $3.5 million for the same period in 2022. The $2.1 million increase was primarily attributed to costs incurred to develop our product pipeline, including MNKD-101 (inhaled clofazimine) and the Afrezza pediatrics clinical study (INHALE-1).
Selling expenses for the first quarter of 2023 were $13.3 million compared to $12.7 million for the same period in 2022. The $0.6 million increase was primarily due to V-Go promotional efforts and increased headcount after the acquisition in the second quarter of 2022 as well as an increase in Afrezza promotional activities, partially offset by the termination of an Afrezza pilot promotional effort targeting primary care physicians which ended in the third quarter of 2022.
General and administrative expenses for the first quarter of 2023 were $10.5 million compared to $7.9 million for the same period in 2022. The $2.6 million increase was primarily attributable to higher stock-based compensation, increased headcount, and higher professional fees.
Interest expense on financing liability was $2.4 million for the first quarter of 2023 and remained consistent with the same period in 2022.
Interest expense on notes was $2.8 million in the first quarter of 2023 and remained consistent with the same period in 2022 due to fixed interest rates and no changes in debt balances.
Cash, cash equivalents and investments as of March 31, 2023 were $166.6 million.
Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKind's website for 14 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding MannKind’s pipeline advancement, including the planned launch of MannKind's inhaled clofazimine trial for patients in the second half of 2023. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with manufacturing and supply, risks associated with product commercialization, risks associated with developing product candidates, risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023, and under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Tyvaso DPI is a trademark of United Therapeutics Corporation.
AFREZZA, MANNKIND, and V-GO are registered trademarks of MannKind Corporation.
MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| MANNKIND CORPORATION AND SUBSIDIARY | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| Three Months Ended March 31, | |||||||
| 2023 | 2022 | ||||||
| (In thousands except per share data) | |||||||
| Revenues: | |||||||
| Net revenue – commercial product sales | $ | 17,562 | $ | 9,826 | |||
| Revenue – collaborations and services | 11,386 | 2,166 | |||||
| Royalties – collaborations | 11,678 | — | |||||
| Total revenues | 40,626 | 11,992 | |||||
| Expenses: | |||||||
| Cost of goods sold | 5,530 | 2,284 | |||||
| Cost of revenue – collaborations and services | 10,683 | 8,714 | |||||
| Research and development | 5,605 | 3,536 | |||||
| Selling | 13,310 | 12,728 | |||||
| General and administrative | 10,542 | 7,969 | |||||
| Loss (gain) on foreign currency transaction | 954 | (1,983 | ) | ||||
| Total expenses | 46,624 | 33,248 | |||||
| Loss from operations | (5,998 | ) | (21,256 | ) | |||
| Other (expense) income: | |||||||
| Interest income, net | 1,302 | 377 | |||||
| Interest expense on financing liability | (2,424 | ) | (2,371 | ) | |||
| Interest expense on notes | (2,786 | ) | (2,748 | ) | |||
| Other income | 111 | — | |||||
| Total other expense | (3,797 | ) | (4,742 | ) | |||
| Loss before income tax expense | (9,795 | ) | (25,998 | ) | |||
| Benefit from income taxes | — | — | |||||
| Net loss | $ | (9,795 | ) | $ | (25,998 | ) | |
| Net loss per share – basic and diluted | $ | (0.04 | ) | $ | (0.10 | ) | |
| Shares used to compute net loss per share – basic and diluted | 263,969 | 251,887 | |||||
| MANNKIND CORPORATION AND SUBSIDIARY | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| March 31, | December 31, | ||||||
| 2023 | 2022 | ||||||
| (In thousands except share and per share data) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 85,869 | $ | 69,767 | |||
| Short-term investments | 80,273 | 101,079 | |||||
| Accounts receivable, net | 19,714 | 16,801 | |||||
| Inventory | 21,998 | 21,772 | |||||
| Prepaid expenses and other current assets | 15,445 | 25,477 | |||||
| Total current assets | 223,299 | 234,896 | |||||
| Property and equipment, net | 54,837 | 45,126 | |||||
| Goodwill | 1,998 | 2,428 | |||||
| Other intangible asset | 1,133 | 1,153 | |||||
| Long-term investments | 492 | 1,961 | |||||
| Other assets | 16,378 | 9,718 | |||||
| Total assets | $ | 298,137 | $ | 295,282 | |||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 13,889 | $ | 11,052 | |||
| Accrued expenses and other current liabilities | 32,995 | 35,553 | |||||
| Financing liability – current | 9,626 | 9,565 | |||||
| Midcap credit facility – current | 11,667 | — | |||||
| Deferred revenue – current | 2,316 | 1,733 | |||||
| Recognized loss on purchase commitments – current | 11,360 | 9,393 | |||||
| Total current liabilities | 81,853 | 67,296 | |||||
| Mann Group convertible note | 8,829 | 8,829 | |||||
| Accrued interest – Mann Group convertible note | 54 | 55 | |||||
| Financing liability – long term | 94,441 | 94,512 | |||||
| Midcap credit facility | 27,704 | 39,264 | |||||
| Senior convertible notes | 225,761 | 225,397 | |||||
| Recognized loss on purchase commitments – long term | 59,829 | 62,916 | |||||
| Operating lease liability | 4,879 | 5,343 | |||||
| Deferred revenue – long term | 45,659 | 37,684 | |||||
| Milestone liabilities | 4,524 | 4,524 | |||||
| Deposits from customer | — | — | |||||
| Total liabilities | 553,533 | 545,820 | |||||
| Stockholders' deficit: | |||||||
| Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2023 and December 31, 2022 | — | — | |||||
| Common stock, $0.01 par value – 400,000,000 shares authorized, 264,278,760 and 263,793,305 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 2,643 | 2,638 | |||||
| Additional paid-in capital | 2,969,225 | 2,964,293 | |||||
| Accumulated deficit | (3,227,264 | ) | (3,217,469 | ) | |||
| Total stockholders' deficit | (255,396 | ) | (250,538 | ) | |||
| Total liabilities and stockholders' deficit | $ | 298,137 | $ | 295,282 | |||
| Last Trade: | US$6.80 |
| Daily Change: | -0.22 -3.13 |
| Daily Volume: | 5,144,699 |
| Market Cap: | US$1.870B |
November 07, 2024 November 05, 2024 November 04, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
